Erratum: Organotypic slice cultures of human glioblastoma reveal difference susceptibilities to treatments(Neuro-Oncology (2013) 16, 6 (670-681) DOI: 10.1093/neuonc/not003);Organotypic slice cultures of human glioblastoma reveal different susceptibilities to treatments

Neuro-Oncology

Volumn 15, Issue 6, 2013, Pages 670-681

  Merz, Felicitas ^a   Gaunitz, Frank ^b   Dehghani, Faramarz ^a   Renner, Christof ^b   Meixensberger, Jürgen ^b   Gutenberg, Angelika ^c   Giese, Alf ^c   Schopow, Kosta ^d   Hellwig, Christian ^a   Schäfer, Michael ^a   Bauer, Manfred ^a   Stöcker, Horst ^e,f   Taucher Scholz, Gisela ^e   Durante, Marco ^e,f   Bechmann, Ingo ^a,f  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d Dr Senckenberg Foundation   (Germany)

^e GSI HELMHOLTZZENTRUM FÜR SCHWERIONENFORSCHUNG GMBH   (Germany)

^f FRANKFURT INSTITUTE FOR ADVANCED STUDIES   (Germany)

Author keywords

glioblastoma multiforme; heavy ions; human test system; organotypic slice culture

Indexed keywords

CARBON; CASPASE 3; GLIAL FIBRILLARY ACIDIC PROTEIN; HISTONE H2AX; KI 67 ANTIGEN; NESTIN; NEUROFILAMENT PROTEIN; TEMOZOLOMIDE; VIMENTIN;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CANCER THERAPY; CANCER TISSUE; CELL DEATH; CELL PROLIFERATION; CELL SUBPOPULATION; CONTROLLED STUDY; DNA DAMAGE; DNA METHYLATION; DOUBLE STRANDED DNA BREAK; DRUG SENSITIVITY; ENZYME ACTIVATION; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IRRADIATION; NERVE CELL; PERSONALIZED MEDICINE; PROMOTER REGION; PROTEIN CLEAVAGE; RADIATION RESPONSE; RADIOSENSITIVITY; TISSUE CULTURE; TISSUE SLICE; TUMOR BIOPSY; X RAY;

EID: 84878280164     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou168     Document Type: Erratum

References (69)

1. Hemmati HD, Nakano I, Lazareff JA, et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A. 2003; 100(25): 15178-15183.
2. Ignatova TN, Kukekov VG, Laywell ED, Suslov ON, Vrionis FD, Steindler DA. Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia. 2002; 39(3): 193-206.
3. Jacques TS, Swales A, Brzozowski MJ, et al. Combinations of genetic mutations in the adult neural stem cell compartment determine brain tumour phenotypes. Embo J. 2010; 29(1): 222-235.
4. Silver DJ, Steindler DA. Common astrocytic programs during brain development, injury and cancer. Trends Neurosci. 2009; 32(6): 303-311.
5. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003; 63(18): 5821-5828.
6. Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012; 483(7390): 479-483.
7. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17(1): 98-110.
8. Sliwa M, Markovic D, Gabrusiewicz K, et al. The invasion promoting effect of microglia on glioblastoma cells is inhibited by cyclosporin A. Brain. 2007; 130(Pt 2): 476-489.
9. Savaskan NE, Heckel A, Hahnen E, et al. Small interfering RNA-mediated xCT silencing in gliomas inhibits neurodegeneration and alleviates brain edema. Nat Med. 2008; 14(6): 629-632.
10. Eke I, Storch K, Kastner I, et al. Three-dimensional invasion of human glioblastoma cells remains unchanged by X-ray and carbon ion irradiation in vitro. Int J Radiat Oncol Biol Phys. 2012; 84(4): e515-e523.
11. Huang PH, Mukasa A, Bonavia R, et al. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci U S A. 2007; 104(31): 12867-12872.
12. Kluge A, Hailer NP, Horvath TL, Bechmann I, Nitsch R. Tracing of the entorhinal-hippocampal pathway in vitro. Hippocampus. 1998; 8(1): 57-68.
13. Hailer NP, Wirjatijasa F, Roser N, Hischebeth GT, Korf HW, Dehghani F. Astrocytic factors protect neuronal integrity and reduce microglial activation in an in vitro model of N-methyl-D-aspartate-induced excitotoxic injury in organotypic hippocampal slice cultures. Eur J Neurosci. 2001; 14(2): 315-326.
14. Dehghani F, Hischebeth GT, Wirjatijasa F, Kohl A, Korf HW, Hailer NP. The immunosuppressant mycophenolate mofetil attenuates neuronal damage after excitotoxic injury in hippocampal slice cultures. Eur J Neurosci. 2003; 18(5): 1061-1072.
15. Eyupoglu IY, Savaskan NE, Brauer AU, Nitsch R, Heimrich B. Identification of neuronal cell death in a model of degeneration in the hippocampus. Brain Res Brain Res Protoc. 2003; 11(1): 1-8.
16. Prodinger C, Bunse J, Kruger M, et al. CD11c-expressing cells reside in the juxtavascular parenchyma and extend processes into the glia limitans of the mouse nervous system. Acta Neuropathol. 2011; 121(4): 445-458.
17. Schaefer L, Babelova A, Kiss E, et al. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest. 2005; 115(8): 2223-2233.
18. Senner V, Ratzinger S, Mertsch S, Grassel S, PaulusW. Collagen XVI expression is upregulated in glioblastomas and promotes tumor cell adhesion. FEBS Lett. 2008; 582(23-24): 3293-3300.
19. Moreth K, Brodbeck R, Babelova A, et al. The proteoglycan biglycan regulates expression of the B cell chemoattractant CXCL13 and aggravates murine lupus nephritis. J Clin Invest. 2010; 120(12): 4251-4272.
20. Merline R, Moreth K, Beckmann J, et al. Signaling by the matrix proteoglycan decorin controls inflammation and cancer through PDCD4 and microRNA-21. Sci Signal. 2011; 4(199): ra75.
21. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999; 5(2): 157-163.
22. Nitsch R, Bechmann I, Deisz RA, et al. Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Lancet. 2000; 356(9232): 827-828.
23. Dowsing T, Kendall MJ. The Northwick Park tragedy - protecting healthy volunteers in future first-in-man trials. J Clin Pharm Ther. 2007; 32(3): 203-207.
24. Kenter MJ, Cohen AF. Establishing risk of human experimentation with drugs: lessons from TGN1412. Lancet. 2006; 368(9544): 1387-1391.
25. Merz F, Bechmann I. Irradiation of human tumor tissue cultures: optimizing ion radiation therapy. Future Oncol. 2011; 7(4): 489-491.
26. Liu Y, Lang F, Xie X, et al. Efficacy of adenovirally expressed soluble TRAIL in human glioma organotypic slice culture and glioma xenografts. Cell Death Dis. 2011; 2: e121.
27. Vaira V, Fedele G, Pyne S, et al. Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proc Natl Acad Sci U S A. 2010; 107(18): 8352-8356.
28. Durante M, Loeffler JS. Charged particles in radiation oncology. Nat Rev Clin Oncol. 2010; 7(1): 37-43.
29. Pignalosa D, Durante M. Overcoming resistance of cancer stem cells. Lancet Oncol. 2012; 13(5): e187-e188.
30. Combs SE, Jakel O, Haberer T, Debus J. Particle therapy at the Heidelberg Ion Therapy Center (HIT) - integrated research-driven university-hospital-based radiation oncology service in Heidelberg, Germany. Radiother Oncol. 2010; 95(1): 41-44.
31. Muller M, Durante M, Stocker H, Merz F, Bechmann I. Modeling radiation effects at the tissue level. Eur Phys J D. 2010; 60(1): 171-176.
32. Merz F, Muller M, Taucher-Scholz G, et al. Tissue slice cultures from humans or rodents: a new tool to evaluate biological effects of heavy ions. Radiat Environ Biophys. 2010; 49(3): 457-462.
33. Haberer T, Becher W, Schardt D, Kraft G. Magnetic scanning system for heavy ion therapy. Nucl Instrum Meth Phys Res Sect A. 1993; 330(1-2): 296-305.
34. Bauer R, Ratzinger S, Wales L, et al. Inhibition of collagen XVI expression reduces glioma cell invasiveness. Cell Physiol Biochem. 2011; 27(3-4): 217-226.
35. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983; 31(1): 13-20.
36. Pilch DR, Sedelnikova OA, Redon C, Celeste A, Nussenzweig A, Bonner WM. Characteristics of gamma-H2AX foci at DNA double-strand breaks sites. Biochem Cell Biol. 2003; 81(3): 123-129.
37. Prise KM, Schettino G, Folkard M, Held KD. New insights on cell death from radiation exposure. Lancet Oncol. 2005; 6(7): 520-528.
38. Jeggo PA, Lobrich M. DNA double-strand breaks: their cellular and clinical impact? Oncogene. 2007; 26(56): 7717-7719.
39. Tobias F, Durante M, Taucher-Scholz G, Jakob B. Spatiotemporal analysis of DNA repair using charged particle radiation. Mutat Res. 2010; 704(1-3): 54-60.
40. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA doublestranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 1998; 273(10): 5858-5868.
41. Keogh MC, Kim JA, Downey M, et al. A phosphatase complex that dephosphorylates gammaH2AX regulates DNA damage checkpoint recovery. Nature. 2006; 439(7075): 497-501.
42. Fukushima T, Takeshima H, Kataoka H. Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT. Anticancer Res. 2009; 29(11): 4845-4854.
43. Bei R, Marzocchella L, Turriziani M. The use of temozolomide for the treatment of malignant tumors: clinical evidence and molecular mechanisms of action. Recent Pat Anticancer Drug Discov. 2010; 5(3): 172-187.
44. Becker KP, Yu J. Status quo - standard-of-care medical and radiation therapy for glioblastoma. Cancer J. 2012; 18(1): 12-19.
45. Johnson DR, Chang SM. Recent medical management of glioblastoma. Adv Exp Med Biol. 2012; 746: 26-40.
46. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10): 987-996.
47. Tisdale MJ. Antitumor imidazotetrazines - XV. Role of guanine O6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones. Biochem Pharmacol. 1987; 36(4): 457-462.
48. Denny BJ, Wheelhouse RT, Stevens MF, Tsang LL, Slack JA. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry. 1994; 33(31): 9045-9051.
49. Danson SJ, Middleton MR. Temozolomide: a novel oral alkylating agent. Expert Rev Anticancer Ther. 2001; 1(1): 13-19.
50. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352(10): 997-1003.
51. Kim YS, Kim SH, Cho J, et al. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomidebased chemoradiotherapy: a single-institution study. Int J Radiat Oncol Biol Phys. 2012; 84(3): 661-667.
52. Christians A, Hartmann C, Benner A, et al. Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma. PLoS One. 2012; 7(3): e33449.
53. Shah N, Lin B, Sibenaller Z, et al. Comprehensive analysis of MGMT promoter methylation: correlation with MGMT expression and clinical response in GBM. PLoS One. 2011; 6(1): e16146.
54. van Nifterik KA, van den Berg J, van der Meide WF, et al. Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide. Br J Cancer. 2010; 103(1): 29-35.
55. Kitange GJ, Carlson BL, Mladek AC, et al. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model. J Neurooncol. 2009; 92(1): 23-31.
56. Gahwiler BH. Slice cultures of cerebellar, hippocampal and hypothalamic tissue. Experientia. 1984; 40(3): 235-243.
57. Tobias CA, Blakely EA, Alpen EL, et al. Molecular and cellular radiobiology of heavy ions. Int J Radiat Oncol Biol Phys. 1982; 8(12): 2109-2120.
58. Chatterjee A, Takada E, TorikoshiM, Kanazawa M. Diagnostic imaging by energetic radioactive particle beams: applications in Bragg peak cancer therapy. Nucl Phys A. 1997; A616(1-2): 478c-489c.
59. Eickhoff H, Haberer T, Kraft G, et al. The GSI Cancer Therapy Project. Strahlenther Onkol. 1999; 175(suppl 2): 21-24.
60. Gademann G, Hartmann GH, Kraft G, Lorenz WJ, Wannenmacher M. The medical heavy ion therapy project at the Gesellschaft fur Schwerionenforschung facility in Darmstadt. Strahlenther Onkol. 1990; 166(1): 34-39.
61. Schulz-Ertner D, Tsujii H. Particle radiation therapy using proton and heavier ion beams. J Clin Oncol. 2007; 25(8): 953-964.
62. Oishi T, Sasaki A, Hamada N, et al. Proliferation and cell death of human glioblastoma cells after carbon-ion beam exposure: morphologic and morphometric analyses. Neuropathology. 2008; 28(4): 408-416.
63. Combs SE, Bohl J, Elsasser T, et al. Radiobiological evaluation and correlation with the local effect model (LEM) of carbon ion radiation therapy and temozolomide in glioblastoma cell lines. Int J Radiat Biol. 2009; 85(2): 126-137.
64. Mizoe JE, Tsujii H, Hasegawa A, et al. Phase I/II clinical trial of carbon ion radiotherapy for malignant gliomas: combined X-ray radiotherapy, chemotherapy, and carbon ion radiotherapy. Int J Radiat Oncol Biol Phys. 2007; 69(2): 390-396.
65. Combs SE, Kieser M, Rieken S, et al. Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the CLEOPATRA trial. BMC Cancer. 2010; 10: 478.
66. Skiriute D, Vaitkiene P, Saferis V, et al. MGMT, GATA6, CD81, DR4, and CASP8 gene promoter methylation in glioblastoma. BMC Cancer. 2012; 12: 218.
67. Nakada M, Furuta T, Hayashi Y, Minamoto T, Hamada J. The strategy for enhancing temozolomide against malignant glioma. Front Oncol. 2012; 2: 98.
68. Everhard S, Tost J, El Abdalaoui H, et al. Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas. Neuro Oncol. 2009; 11(4): 348-356.
69. Holdhoff M, Ye X, Blakeley JO, et al. Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas. J Neurooncol. 2012; 110(2): 279-285.